NeuroVision has announced completion of a nonexclusive license agreement with Janssen Research & Development LLC, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, that will significantly expand the companies’ collaboration.
NeuroVision Imaging, LLC (NeuroVision) is developing a breakthrough, low cost, non-invasive, eye imaging system for measuring autofluorescence which can potentially detect amyloid beta (Aβ) plaque in the eye.
Retinal Imaging Test
Aβ plaque deposits in the brain are a hallmark sign of Alzheimer’s disease, and histological evidence shows that Aβ plaque also accumulates in the retina, the photoreceptor and nerve complex at the rear of the eye.
Alzheimer’s disease and other dementias will grow each year as the size and proportion of the population aged 65 and older continue to increase. By 2050, the number of people with Alzheimer’s disease is estimated to increase 300% and reach 131 million.